JP4476811B2 - Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ - Google Patents

Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ Download PDF

Info

Publication number
JP4476811B2
JP4476811B2 JP2004546667A JP2004546667A JP4476811B2 JP 4476811 B2 JP4476811 B2 JP 4476811B2 JP 2004546667 A JP2004546667 A JP 2004546667A JP 2004546667 A JP2004546667 A JP 2004546667A JP 4476811 B2 JP4476811 B2 JP 4476811B2
Authority
JP
Japan
Prior art keywords
group
adenine
phosphonylmethoxypropyl
pyridyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004546667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511490A5 (enExample
JP2006511490A (ja
Inventor
ケイ・ラジャ・レディ
マーク・ディ・エライオン
マイケル・シー・マテリッチ
ジョゼフ・ジェイ・コプチョ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of JP2006511490A publication Critical patent/JP2006511490A/ja
Publication of JP2006511490A5 publication Critical patent/JP2006511490A5/ja
Application granted granted Critical
Publication of JP4476811B2 publication Critical patent/JP4476811B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004546667A 2002-05-13 2003-05-12 Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ Expired - Fee Related JP4476811B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38054502P 2002-05-13 2002-05-13
PCT/US2003/014821 WO2004037161A2 (en) 2002-05-13 2003-05-12 Cyclic prodrugs of pmea one of its analogues

Publications (3)

Publication Number Publication Date
JP2006511490A JP2006511490A (ja) 2006-04-06
JP2006511490A5 JP2006511490A5 (enExample) 2006-06-29
JP4476811B2 true JP4476811B2 (ja) 2010-06-09

Family

ID=32176361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004546667A Expired - Fee Related JP4476811B2 (ja) 2002-05-13 2003-05-12 Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ

Country Status (9)

Country Link
US (1) US7214668B2 (enExample)
EP (2) EP2223927B1 (enExample)
JP (1) JP4476811B2 (enExample)
AU (1) AU2003299492B2 (enExample)
CA (1) CA2485702C (enExample)
IL (2) IL164809A0 (enExample)
NZ (1) NZ536328A (enExample)
TW (1) TWI347325B (enExample)
WO (1) WO2004037161A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU2003235501A1 (en) * 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
PL376474A1 (en) * 2002-10-31 2005-12-27 Metabasis Therapeutics, Inc. Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
CA2553455A1 (en) * 2004-01-21 2005-08-11 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
MXPA06014013A (es) * 2004-06-08 2007-03-15 Metabasis Therapeutics Inc Sintesis mediada por acidos de lewis de esteres ciclicos.
NZ554783A (en) * 2004-11-15 2010-12-24 Ceptyr Inc Protein tyrosine phosphatase inhibitors and methods of use thereof
US7737273B2 (en) 2005-07-26 2010-06-15 Hetero Drugs Limited Process for acyclic phosphonate nucleotide analogs
US20070042501A1 (en) * 2005-08-20 2007-02-22 Institute Of Nuclear Energy Research A novel technology for the purity assay of TRODAT-1 raw material
ATE534377T1 (de) * 2006-05-16 2011-12-15 Gilead Sciences Inc Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
CN101371841A (zh) * 2007-08-23 2009-02-25 浙江医药股份有限公司新昌制药厂 结晶型恩替卡韦制剂及其制备方法和应用
JP2009196959A (ja) * 2008-02-25 2009-09-03 Yamaguchi Univ がん治療用医薬組成物
CN101475594B (zh) * 2009-02-06 2012-05-30 廖国超 肝靶向抗病毒前体药物环状磷酸酯及其应用
CN101659676B (zh) * 2009-09-07 2012-06-20 徐奎 一种硫代阿德福韦、替诺福韦肝靶向酯前体药物
US8940313B2 (en) 2010-04-23 2015-01-27 University Of Southern California Tyrosine-based prodrugs of antiviral agents
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
WO2012062835A1 (en) * 2010-11-12 2012-05-18 Glaxo Wellcome Manufacturing Pte Ltd Novel pharmaceutical compositions
WO2012079035A1 (en) 2010-12-10 2012-06-14 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
WO2012154698A2 (en) 2011-05-06 2012-11-15 Mckenna Charles E Method to improve antiviral activity of nucleotide analogue drugs
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN103333209B (zh) * 2013-07-05 2015-09-30 西安新通药物研究有限公司 替诺福韦前药(hts)新晶体
CN104710477A (zh) * 2013-12-16 2015-06-17 安徽贝克联合制药有限公司 替诺福韦环膦酸酯化合物及其药学上可接受的盐和其制备方法及应用
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
MX2016011897A (es) 2014-03-14 2017-04-27 Alltech Inc Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
WO2017048252A1 (en) 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
CN107540710B (zh) * 2016-06-24 2020-10-16 浙江柏拉阿图医药科技有限公司 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
WO2017220028A1 (zh) 2016-06-24 2017-12-28 浙江柏拉阿图医药科技有限公司 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
WO2019139919A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CN108863797B (zh) * 2018-07-02 2021-01-15 吉首大学 一类3-(取代/非取代苯基)-3-羟基丙酰氧肟酸的制备方法
CN116178440B (zh) * 2022-12-23 2025-12-30 杏林中医药科技(广州)有限公司 一种肝脏靶向烷化剂及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE554888A (enExample) * 1956-12-20
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
US4579849A (en) 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
FR2562543B1 (fr) * 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
EP0338372A3 (en) 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
DE68924456T2 (de) 1988-08-02 1996-05-30 Nissan Chemical Ind Ltd Mittel zur Verbesserung von Arzneimitteleffekten für Antitumormittel.
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
CS276072B6 (en) * 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5157027A (en) * 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
GB9205917D0 (en) 1992-03-18 1992-04-29 Smithkline Beecham Plc Pharmaceuticals
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
DE69426904T2 (de) 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
ATE486882T1 (de) 1993-09-17 2010-11-15 Gilead Sciences Inc Nukleotidanaloge
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
AU2808495A (en) 1994-07-04 1996-01-25 Takeda Chemical Industries Ltd. Phosphonic acid compounds, their production and use
DE4445829A1 (de) 1994-12-22 1996-06-27 Leybold Ag Gegenstrom-Schnüffellecksucher
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
DK0871454T3 (da) 1995-07-17 2004-03-22 Cephalon Inc Phosphorholdige inhibitorer af cystein- og serinprotease
US5962440A (en) * 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
ES2187991T3 (es) 1997-07-25 2003-06-16 Gilead Sciences Inc Composiciones de analogo de nucleotido.
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CZ297264B6 (cs) * 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
WO2000038666A2 (en) 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
SK12442001A3 (sk) 1999-03-05 2002-06-04 Metabasis Therapeutics, Inc. Cyklické fosforamidáty, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú
JP4979866B2 (ja) * 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
AU2003235501A1 (en) * 2002-05-13 2003-11-11 Metabasis Therapeutics, Inc. PMEA and PMPA cyclic producing synthesis
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
PL376474A1 (en) * 2002-10-31 2005-12-27 Metabasis Therapeutics, Inc. Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
US7553825B2 (en) * 2003-12-30 2009-06-30 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
MXPA06014013A (es) * 2004-06-08 2007-03-15 Metabasis Therapeutics Inc Sintesis mediada por acidos de lewis de esteres ciclicos.

Also Published As

Publication number Publication date
IL164809A (en) 2012-08-30
AU2003299492A1 (en) 2004-05-13
US20030229225A1 (en) 2003-12-11
NZ536328A (en) 2007-11-30
TWI347325B (en) 2011-08-21
EP1532157A4 (en) 2009-02-25
CA2485702A1 (en) 2004-05-06
TW200426152A (en) 2004-12-01
EP2223927A3 (en) 2010-09-15
EP1532157A2 (en) 2005-05-25
EP2223927A2 (en) 2010-09-01
US7214668B2 (en) 2007-05-08
CA2485702C (en) 2011-07-19
JP2006511490A (ja) 2006-04-06
IL164809A0 (en) 2005-12-18
WO2004037161A2 (en) 2004-05-06
WO2004037161A3 (en) 2005-03-31
AU2003299492B2 (en) 2010-06-10
EP2223927B1 (en) 2014-10-15

Similar Documents

Publication Publication Date Title
EP2223927B1 (en) Salts of a phosphonic acid based prodrug of PMEA
CA2171743C (en) Nucleotide analogs
US7582758B2 (en) Lewis acid mediated synthesis of cyclic esters
AU2002230230B2 (en) Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same
US5798340A (en) Nucleotide analogs
EP1778249B1 (en) Phosphonate prodrugs of a 2'-fluoro-2',3'-didehydro-2',3'-dideoxyadenosine analogue as anti-hiv agents
KR100386685B1 (ko) 뉴클레오타이드동족체류
CN103980318B (zh) 含有取代苄基的核苷磷酸酯前药及其制备方法和用途
JP2009504677A (ja) 新規２’−ｃ−メチル及び４’−ｃ−メチルヌクレオシド誘導体
WO2008100447A2 (en) Nucleoside analogs for antiviral treatment
JP2007522237A (ja) 新規２’−ｃ−メチルヌクレオシド誘導体
AU2013349750A1 (en) Phosphonucleosides useful in the treatment of viral disorders
US5693771A (en) Methods for making nucleoside analogs
WO2004096287A2 (en) Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
KR20040027452A (ko) (1-포스포노메톡시-2-알킬사이클로프로필)메틸뉴클레오사이드유도체의 (+)-트랜스 이성질체, 그의 입체이성질체의제조방법 및 항바이러스제로서의 용도
HUE028077T2 (en) Nucleosides to suppress or reduce the development of resistance during cytostatic treatment
Alanazi Design, synthesis, and biological evaluation of novel nucleotide prodrugs as potential therapeutics
HK1103648B (en) Phosphonate prodrugs of a 2'-fluoro-2',3'-didehydro-2',3'-dideoxyadenosine analogue as anti-hiv agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060511

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090901

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100310

R150 Certificate of patent or registration of utility model

Ref document number: 4476811

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140319

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees